PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time

Core Viewpoint - PDS Biotechnology Corporation is set to provide a clinical program update on August 1, 2024, focusing on its immunotherapy developments and upcoming pivotal clinical trials [1][2]. Company Overview - PDS Biotechnology is a late-stage immunotherapy company dedicated to enhancing the immune system's ability to target and eliminate cancers, as well as developing vaccines for infectious diseases [2]. - The company plans to initiate a pivotal clinical trial in 2024 for its lead program targeting advanced HPV16-positive head and neck squamous cell cancers [2]. Clinical Development - The lead investigational targeted immunotherapy, Versamune® HPV, is being developed in combination with a standard immune checkpoint inhibitor and in a triple combination with PDS01ADC, an IL-12 fused antibody drug conjugate (ADC), along with a standard immune checkpoint inhibitor [2].